Abstract: A two-compartment capsule includes a body, a diaphragm between which seals off the body and provides a first compartment to hold a first ingredient, and a cap applied to the body whereby a space between the inner portion of the cap and the diaphragm defines a second compartment for holding a second ingredient. This disclosure also provides certain ranges for the volumes of the first compartment and the second compartment, as well as a volume ratio of the first compartment to the second compartment, lengths of the first and second compartments, and the length of contact between a sidewall of the diaphragm and a sidewall of the body. Furthermore, particular ingredients and formulations for the two-compartment capsule where volume is critical for a therapeutic effect are disclosed.

Abstract: Provided is a bone fixation material that does not deteriorate in properties even by an electron beam sterilization treatment performed before or during use as a bone fixation material, has fatigue resistance, wear resistance, and dimensional stability at excellent levels, also has biocompatibility, and offers excellent osteoconnectivity. The bone fixation material according to the present invention includes a nonwoven fabric made of PEEK fibers. The bone fixation material according to the present invention preferably has an average pore size of 3 to 280 ?m and preferably has a porosity of 15% to 70%. The PEEK fibers preferably have an average fiber diameter of 10 ?m or less.

Abstract: Provided herein are drug implants comprising a therapeutically active agent for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and a therapeutically active agent disposed therein. Additionally provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may comprise bicalutamide, e.g., for use in the treatment of prostate cancer.

Abstract: The present disclosure relates to compositions and methods for inhibiting inflammation and reducing the risk of spreading sexually transmitted diseases using an alginic acid-based antimicrobial compound. Such compositions provide dual protection by (1) attacking and inactivating viruses and other microbes and (2) blocking the host response that viruses trigger to invade host cells. Such compositions can also be part of an acid buffering contraceptive.

Abstract: Provided herein are drug implants comprising a therapeutically active agent for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and a therapeutically active agent disposed therein. Additionally provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may comprise bicalutamide, e.g., for use in the treatment of prostate cancer.

Abstract: The present invention is directed towards the cosmetic use of at least one compound of formula (I) and/or solvates thereof and/or stereoisomers thereof: in which groups A and B are different and: A-* represents a disubstituted phenyl radical: B-** represents a mono- or disubstituted phenyl radical: or of a composition comprising, in a physiologically acceptable medium, at least one compound of formula (I), for treating and/or preventing the signs of ageing and/or of photoageing of keratin materials, preferably of the skin.

Abstract: A solubilisate consisting of curcumin in a quantity of less than or equal to 10% by weight, preferably less than or equal to 7.5% by weight, particularly preferably 6% by weight, and at least one emulsifier having an HLB value in the range between 13 and 18, in particular polysorbate 80 or polysorbate 20 or a mixture of polysorbate 20 and polysorbate 80, wherein the average diameter of the micelles loaded with curcumin is between 5 nm and 40 nm, preferably between 6 nm and 20 nm, particularly preferably between 7 nm and 10 nm.

Abstract: The present invention provides a sunscreen composition comprising one or more oil soluble UV filters, at least about 20 weight percent ethanol, about 13.5 weight percent or less of a low viscosity silicone having a viscosity of at least 20 centistokes, and at least about 23 weight percent of a super low viscosity silicone having a viscosity up to about 15 centistokes, wherein the composition is anhydrous and transparent.

Abstract: Disclosed is a microneedle including at least one tip portion that is capable of penetrating the skin and includes a liquid medicine melted in the skin; a base portion supporting the at least one tip portion; and at least one guide portion that is provided between the at least one tip portion and the base portion, is made of a non-soluble material, and is protruded in a direction in which the at least one tip portion penetrates the skin to couple with the at least one tip portion. In accordance with such a configuration, the at least one tip portion may be instantly separated in a short time, whereby superior liquid medicine supplyability is exhibited.

Abstract: Provided herein are drug implants comprising a therapeutically active agent for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and a therapeutically active agent disposed therein. Additionally provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may comprise bicalutamide, e.g., for use in the treatment of prostate cancer.

Abstract: Disclosed herein is a carbon quantum dot produced by the step of subjecting dopamine and spermine to a pyrolysis treatment at 250° C. Also disclosed herein is use of the carbon quantum dot for treating a bacterial infection, and for inhibiting bacterial growth and biofilm formation.

Abstract: The present invention provides a conductive hydrogel comprising a polystyrene sulfonate compound selected from poly(3,4-ethylenedioxythiophene) polystyrene sulfonate (PEDOT:PSS), reduced graphene oxide polystyrene sulfonate (rGO:PSS) and rGO:PEDOT:PSS; and a conjugate of polyethylene glycol (PEG) and a linker-(BX)n oligopeptide of formula (I) PEG-linker-(BX)n??(I) wherein B is lysine or arginine, X is selected from alanine, glycine, serine, threonine, tyrosine, glutamic acid or aspartic acid and n is an integer selected from 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20. The invention further relates to processes for assembling the conductive hydrogel. The conductive hydrogel can be used in various biomedical applications, such as neuroprostheses, biosensors, nerve grafts, cell culture and encapsulation of cells and microorganisms as well as for drug delivery.

Abstract: The present invention is directed toward fatty acid-based particles, and methods of making such particles. The particles can be associated with an additional, therapeutic agent. Also provided herein is a method of forming fatty acid particles, comprising associating a cross-linked, fatty acid-derived biomaterial with a cryogenic liquid; and fragmenting the bio material/cryogenic liquid composition, such that fatty acid particles are formed. The particles can be used for a variety of therapeutic applications.

Abstract: A multi-compartment capsule may include a body, a diaphragm between, which seals off the body and provides a first compartment to hold an ingredient, and a cap applied to the body whereby a space between the inner portion of the cap and the diaphragm defines a second compartment for holding an oil. A two-compartment capsule may include a body, a diaphragm between, which seals off the body and provides a first compartment to hold an oil, and a cap applied to the body whereby a space between the inner portion of the cap and the diaphragm defines a second compartment for holding an ingredient. The ingredient may have increased bioavailability after exposure to the oil. This disclosure also provides particular formulations for use in such a capsule.

Abstract: The solid preparation which improved the dissolution profile and the stability of the 6,7-unsaturation-7-carbamoyl morphinan derivative is provided. When 6,7-unsaturation-7-carbamoyl morphinan derivative, croscarmellose sodium and ferric oxide were contained, not titanium oxide in the solid preparations and the coating solid preparations, a dissolution rate after 15 minutes of the dissolution test is more than 85%, and stability, particularly, light stability can be improve.

Abstract: Exemplary embodiments of the present invention provide adhesion barriers having anti-adhesion and tissue fixating properties. The adhesion barriers are formed of fatty acid based films. The fatty acid-based films may be formed from fatty acid-derived biomaterials. The films may be coated with, or may include, tissue fixating materials to create the adhesion barrier. The adhesion barriers are well tolerated by the body, have anti-inflammation properties, fixate, well to tissue, and have a residence time sufficient to prevent post-surgical adhesions.

Abstract: The present invention relates to: an oil-in-water emulsion composition having a viscosity of 1,500-50,000 cps, and comprising an anionic surfactant and a sugar surfactant so as to satisfy the following relational expression 1; and a cosmetic composition containing the same. [Relational expression 1] 0.01?A/B?1 (In relational expression 1, A is the wt % of the anionic surfactant, and B is the wt % of the sugar surfactant, wherein the wt % of each ingredient is based on the total weight of the composition, and B is 1-30 wt %.

Abstract: Provided herein is a nutritional supplement designed to support kidney and cardiac function as well as mitochondrial energy function needs in patients undergoing hemodialysis. This supplement replenishes essential vitamins and minerals that are lost during dialysis, does not contain compounds that may specifically cause harm to dialysis patients, and provides support for tissues undergoing oxidative stress.

Abstract: The present invention is in the field of delivering an active substance to the oral cavity and relates to mucoadhesive active composition and corresponding mucoadhesive dosage form, which can deliver an active substance within the oral cavity, especially an orodispersible tablet for delivering probiotic substance. The present invention also relates to a method of producing the said composition and a method of processing the composition into a mucoadhesive dosage form, especially an orodispersible tablet. The present invention moreover relates to a system and a method for testing the mucoadhesion of a dosage form.

Abstract: Crystalline microparticles consisting of a phenylalkylamino beta2-adrenergic agonist coated with a C12-C20 fatty acid are useful for the preparation of pharmaceutical aerosol formulations in form of suspension in a liquefied propellant gas or powder formulations.